Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 6,439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Withdrawn Not applicable Interventional

Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate

NCT02639624
View directory record Official record
Conditions
Renal Dialysis, Hemodialysis
Interventions
Low bicarbonate dialysate First, Normal bicarbonate dialysate First, Normal bicarbonate dialysate, Low bicarbonate dialysate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT07571746
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

NCT00032188
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
aldesleukin, bryostatin 1, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 29, 2026, 5:48 PM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 29, 2026, 5:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

NCT07106879
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions
Blood Work
Other
Lead sponsor
Clindove Research LLC
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 29, 2026, 5:48 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass

NCT03331146
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Saline, Sodium Nitrite
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 29, 2026, 5:48 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Interventions
MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 29, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

NCT00158886
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Topotecan, Radiation therapy
Drug · Radiation
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Advanced Kidney Cancer

NCT00011973
View directory record Official record
Conditions
Kidney Cancer
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Detroit, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 29, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional

Regional Erector Spinae Analgesic Block vs Standard of Care Undergoing Percutaneous Nephrolithotomy

NCT04663269
View directory record Official record
Conditions
Kidney Stone, Surgery
Interventions
4mg PF Dexamethasone, Control Test
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Podocyte Retinoids

NCT00098020
View directory record Official record
Conditions
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

NCT00625820
View directory record Official record
Conditions
Kidney Disease, Albuminuria
Interventions
6R BH4, Vitamin C
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

NCT03690362
View directory record Official record
Conditions
Pharmacokinetics
Interventions
VNRX-5133 and VNRX-5022
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 29, 2026, 5:48 PM EDT
Completed No phase listed Observational

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

NCT03859388
View directory record Official record
Conditions
Rejection Chronic Renal, Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 5:48 PM EDT
Not listed Not applicable Interventional

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

NCT01017627
View directory record Official record
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 29, 2026, 5:48 PM EDT
Not listed No phase listed Observational

Observational Study of BIS in Hemodialysis Patients

NCT05381961
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Failure Chronic, Hemodialysis
Interventions
Bioimpedance spectroscopy (BIS) measurement, SOZO device
Device
Lead sponsor
ImpediMed Limited
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

NCT00478361
View directory record Official record
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Springfield, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 29, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional Results available

Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases

NCT00540969
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cryosurgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Fondaparinux in Critically Ill Patients With Renal Failure

NCT01467583
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Fondaparinux
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study

NCT00890045
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 29, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339
View directory record Official record
Conditions
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
NBTXR3, SABR, Nivolumab, Pembrolizumab
Drug · Radiation
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 29, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
BI 10773, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Plantation, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 29, 2026, 5:48 PM EDT
Not yet recruiting Phase 2 Interventional

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

NCT07645300
View directory record Official record
Conditions
Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
Interventions
phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone, phase 2B Chlorthalidone LD + Spironolactone LD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 5:48 PM EDT